novo nordisk lawsuit semaglutide A/S is asking a federal judge to halt Eli Lilly & Co.'s advertisements for its GLP-1 drugs, escalating a legal fight against the company's campaign for weight loss treatments Novo Nordisk sues Hims &

The Phase 2 NEJM trial (2023) Published in the New England Journal of Medicine under the title "Triple-Hormone-Receptor Agonist Retatrutide for Obesity," this trial (NCT04881760) enrolled 338 adults and ran for 48 weeks

A comprehensive review of conventional and stimuli-responsive delivery systems for bioactive peptides: from food to biomedical applications

Yes, creatine has no contraindications with reduced renal function and can be safely initiated

Following the TRIUMPH-2 and TRIUMPH-3 results announced on 23 July 2026, Eli Lilly has confirmed it intends to file for approval in the first quarter of 2027 which places realistic UK availability in 2028 at the earliest

This reaction is catalyzed by proteins of the ADH family [56], of which class I (ADH1) and III (ADH3) enzymes metabolize ethanol in the liver [57, 58]